Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 8/20 | 0.43 |
| ▸ | ST6GAL1 | P15907 | 6/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18415627 | 1.00 | CD22 (0.43) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL16645359 | 0.96 | ST6GAL1 (0.44) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL20832121 | 0.95 | ST6GAL1 (0.42) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL18073816 | 0.95 | ST6GAL1 (0.42) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL18084276 | 0.92 | ST6GAL1 (0.40) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL2605862 | 0.92 | ST6GAL1 (0.40) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL10187590 | 0.92 | ST6GAL1 (0.45) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL18494422 | 0.92 | ST6GAL1 (0.47) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL18713167 | 0.91 | ST6GAL1 (0.43) | CD22ST6GAL1P2RY2P2RY4P2RY6 | |
| SCHEMBL17000271 | 0.91 | ST6GAL1 (0.43) | CD22ST6GAL1P2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135275-B2 | Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets | NOVO NORDISK HEALTHCARE AG (CH) | 2021-10-05 | — | — | US | disclosed |
| US-20190083587-A1 | Coagulation factor-targeting to TLT-1 on activated platelets | NOVO NORDISK AS (DK) | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083587-A1 | Coagulation factor-targeting to TLT-1 on activated platelets | TFPI, F13B, F3 | CD22 1371/4885ST6GAL1 206/4885P2RY2 3043/4885 |
| US-11135275-B2 | Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets | TFPI, F3, F11 | CD22 890/4885ST6GAL1 232/4885P2RY2 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.